The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review
Author:
Funder
Mundipharma Research Limited
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
https://link.springer.com/content/pdf/10.1007/s13300-022-01228-w.pdf
Reference117 articles.
1. Wilding J, Fernando K, Milne N, et al. SGLT2 inhibitors in Type 2 diabetes management: key evidence and implications for clinical practice. Diabetes Ther. 2018;9(5):1757–73.
2. Ali A, Bain S, Hicks D, Newland, et al. SGLT2 inhibitors: cardiovascular benefits beyond HbA1c-translating evidence into practice. Diabetes Ther. 2019;10(5):1595–622.
3. Wheeler DC, James J, Patel D, et al. SGLT2 inhibitors: slowing of chronic kidney disease progression in Type 2 diabetes. Diabetes Ther. 2020;11(12):2757–74.
4. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.
5. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes;Current Atherosclerosis Reports;2023-12-27
2. Antihypertensive Effects of SGLT2-Inhibitors: Considerations for Clinical Practice;Current Vascular Pharmacology;2023-12-18
3. The role of sodium-glucose cotransporter type 2 inhibitors on the path to cardiovascular well-being in type 2 diabetes mellitus and chronic kidney disease;FOCUS. Endocrinology;2023-05-10
4. An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program;Expert Review of Endocrinology & Metabolism;2023-03-04
5. Deprescribing, Polypharmacy and Prescribing Cascades in Older People with Type 2 Diabetes: A Focused Review;Journal of the Indian Institute of Science;2023-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3